Ravi Vallabhan, MD
Interventional Cardiology · Dallas, TXNPI 1184672602
Payments from drug & device makers
Across 361 payments — averaging $244.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$81K
- Edwards Lifesciences$4K
- Boston Scientific$829
- AstraZeneca$699
- Shockwave Medical, Inc$674
- Abiomed$179
- plus $1K from 22 others
What the payments were for
- Speaking & faculty fees$15,00057%
- Food & beverage$11,08642%
- Education$490%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 151 | $81,144 |
| Edwards Lifesciences | 103 | $3,516 |
| Boston Scientific | 21 | $829 |
| AstraZeneca | 20 | $699 |
| Shockwave Medical, Inc | 16 | $674 |
| Abiomed | 3 | $179 |
| Penumbra, Inc. | 1 | $148 |
| Heartflow, Inc. | 2 | $132 |
| Philips North America LLC | 1 | $125 |
| Cardiovascular Systems Inc. | 1 | $125 |
| E.r. Squibb & Sons, L.L.C. | 6 | $114 |
| Novartis | 4 | $100 |
| Amgen | 5 | $80 |
| Abbott | 3 | $70 |
| Cardiva Medical, Inc. | 1 | $56 |
| Novo Nordisk | 3 | $46 |
| Pfizer | 2 | $41 |
| Spectrawave, Inc | 2 | $40 |
| Amarin Pharma, Inc. | 2 | $36 |
| Sanofi-aventis U.S. LLC | 2 | $35 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $35 |
| Merck | 2 | $33 |
| Regeneron Healthcare Solutions, Inc. | 2 | $28 |
| Bridgebio Pharma, Inc. | 1 | $22 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $21 |
| Lilly USA, LLC | 1 | $14 |
| Itamar Medical Inc | 1 | $13 |
| Osprey Medical Inc | 1 | $1 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CoreValve Evolut$12,376
- COREVALVE EVOLUT R$1,133
- Resolute$600
- SAPIEN 3 Ultra RESILIA$495
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$293
- Vascular Lithotripsy$248
- FARXIGA$229
- Indigo System$148
- Impella$146
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$144
- SYMPLICITY G3$137
- GENERAL - THERAPIES$136
- (6342) Intrasight Integ$125
- Diamondback Coronary$125
- FFRct$116
- GENERAL - STRUCTURAL HEART$111
- GENERAL - STENTS$105
- CROSSBOSS$102
How this compares
$88,357 in reported general payments places this provider in the 80th percentile of 686 interventional cardiology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 409 | $423,775 |
| Repatha SureclickEvolocumab | 199 | $167,183 |
| XareltoRivaroxaban | 127 | $132,292 |
| FarxigaDapagliflozin Propanediol | 93 | $86,743 |
| EntrestoSacubitril/Valsartan | 80 | $82,042 |
| Praluent PenAlirocumab | 27 | $23,632 |
| JardianceEmpagliflozin | 15 | $12,917 |
| Repatha SyringeEvolocumab | 11 | $8,936 |
| Metoprolol Succinate | 522 | $8,125 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 20 | $6,119 |
| Ezetimibe | 205 | $5,180 |
| VascepaIcosapent Ethyl | 23 | $5,061 |
| Rosuvastatin Calcium | 366 | $4,699 |
| Flecainide Acetate | 59 | $4,160 |
| Icosapent Ethyl | 18 | $4,134 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $41 | $423,775409 claims |
| AstraZenecaFarxiga | $699 | $86,74393 claims |
| NovartisEntresto | $100 | $82,04280 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 686 interventional cardiology providers in Texas.
Other interventional cardiology in Dallas
- Robert StolerDallas$8.2M
- James ChoiDallas$5.2M
- Cara Ann EastDallas$3M
- Byung ParkDallas$735K
- Anthony BavryDallas$359K
- Donald WurzburgDallas$341K
- Tony DasDallas$263K
- Zachary RosolDallas$257K
- Srinivasa PotluriPlano$5.1M
- Neal KleimanHouston$4.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.